INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Contingent Liabilities History
[Standalone]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹0.98 Cr | ₹0.95 Cr | ₹0.67 Cr | ₹0.59 Cr | - |
What is the latest Contingent Liabilities ratio of INDO US BIOTECH ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹0.98 Cr |
Mar2023 | ₹0.95 Cr |
Mar2022 | ₹0.67 Cr |
Mar2021 | ₹0.59 Cr |
Mar2020 | - |
How is Contingent Liabilities of INDO US BIOTECH Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹0.98 Cr | 2.84 | |
Mar2023 | ₹0.95 Cr | 42.64 | |
Mar2022 | ₹0.67 Cr | 13.27 | |
Mar2021 | ₹0.59 Cr | 0 | |
Mar2020 | - | - |
Compare Contingent Liabilities of peers of INDO US BIOTECH
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
INDO US BIOTECH | ₹303.5 Cr | -4.4% | -15% | -45.5% | Stock Analytics | |
BOMBAY BURMAH TRADING CORPORATION | ₹12,729.9 Cr | -1.4% | -7.9% | -26.7% | Stock Analytics | |
KAVERI SEED COMPANY | ₹5,989.1 Cr | 8.2% | 4.1% | 2.2% | Stock Analytics | |
VENKYS (INDIA) | ₹2,118.5 Cr | 7.1% | -3.4% | -36.1% | Stock Analytics | |
BOMBAY SUPER HYBRID SEEDS | ₹1,455.8 Cr | 5.9% | 1.3% | -30.4% | Stock Analytics | |
MANGALAM GLOBAL ENTERPRISE | ₹524.7 Cr | -3.6% | -5.9% | NA | Stock Analytics |
INDO US BIOTECH Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
INDO US BIOTECH | -4.4% |
-15% |
-45.5% |
SENSEX | 0.9% |
-1.1% |
0.6% |
You may also like the below Video Courses